Product Code: RP-ID-10151773 |
Published Date: 21 Oct 2022 |
Region: Global |
Category: Healthcare & Pharmaceuticals |
Report ID: 10151773
Market Overview:
Global Renal Disease Treatment Devices Industry Market Research 2030
The global market for renal disease treatment devices is expected to grow rapidly due to the increasing incidence of chronic kidney disease (CRF) and end-stage renal disease (ESRD). Due to the large number of patients with hypertension and lifestyle-related diseases, the need for medical devices may increase during the forecast period as the main cause of the increase in kidney related diseases. Population growth is one of the main drivers for this market. This is because aging is a common and effective factor that increases the prevalence of kidney disease. According to the World Health Organization (WHO) in 2011, more than 190 million people worldwide have chronic kidney disease and 220 million people have prostate disease, a gradual increase over the past decade. The high prevalence of kidney disease has led doctors to use advanced kidney disease treatment tools that can speed up treatment and recovery time. Other market factors are expected to drive the market during the forecast period, including improvements in healthcare infrastructure and introduction of new treatments for kidney disease devices, especially in developed countries. The development of new and safe treatments for kidney disease is contributing to the growth of this market. Advances in technology, such as on-site support systems, and growing interest in maintaining quality of life are some of the growth drivers for this market. Additionally, additional R&D spending, government subsidies, and increasing use of personalized medicines are expected to drive the growth of the kidney disease market over the forecast period. The kidney disease treatment equipment market is split into treatment and equipment. Treatment of kidney disease includes dialysis and a kidney transplant. Hemodialysis equipment has been one of the largest inventories on the market since 2014 due to widespread use by ESRD patients. Urethral treatment equipment, hemodialysis, pelvic hernia treatment, endoscopy, BPH treatment equipment, artificial stent, lithotripsy, sacral nerve correction, urethral anastomosis and various teeth, urethral stent, vaginal vagina and various disc marketing equipment standards. Peritoneal dialysis, catheter ablation and urolithiasis treatment. The dialysis industry has the largest market share due to the high prevalence of CRF. Peritoneal dialysis catheters are less expensive than other dialysis procedures and are widely available to patients. Geographically, the market is divided into North America, Asia Pacific, Latin America, Middle East, Asia and Europe. North America was the most lucrative market in 2020 due to advanced medical centers and supportive government policies. New payment system available in the US On January 1, 2011, the ESRD payment system was introduced. The system combines payments for dialysis, medications, and laboratory tests to manage the cost of dialysis treatment. This should develop the market rapidly. Increasing use of technologically advanced equipment, particularly in hospitals, is driving the growth of the US market during the forecast period. The large database on the elderly and the prevalence of chronic diseases are expected to increase the demand for kidney disease treatment devices in the European market. Rising healthcare costs, untapped opportunities and public funding for research and development in Asia Pacific are expected to strengthen the regional kidney market during the forecast period. Emerging economies such as India and China are major drivers of market growth in the Asia Pacific region. Key players in the market are Fresenius Medical Care, Dornier Medtech, Baxter International, CR Bird and Asahi Casey Company, Jora Pharmaceutical Company, Terumo Company, B. This is the Brown group. Companies are pursuing competitive strategies such as new product development, collaboration, mergers and acquisitions, and partnerships. Baxter International acquires Swedens Ganbello to increase its hemodialysis products and market penetration in Europe. Similarly, La Jollas ongoing pharmaceutical research has shown positive results in phase 2 clinical trials of new drugs such as the drug molecule GSC-100 at CRI, expanding the device market for this drug. kidney disease.
Related Reports
Proof of Quality & Reliability
